Related Experiment Video
Updated: Aug 11, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
Concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer
Chalong Cheewakriangkrai1, Jatupol Srisomboon, Imjai Chitapanarux
1Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Faculty of Medicine, Maharaj Nakorn Chiangmai Hospital, Chiangmai University, Chiang Mai, Thailand. ccheewak@mail.med.cmu.ac.th
Objectives:
To evaluate the outcomes and adverse effects of concurrent cisplatin-based chemoradiation and adjuvant hysterectomy for bulky stage IB-IIA cervical cancer
Material And Method:
All eligible, thirty-four patients with bulky stage IB-IIA cervical cancer were assigned to receive weekly cisplatin 40 mg/m2 for 6 cycles concurrently with radiation followed by extrafascial hysterectomy 6 weeks after completion of radiation.
Results:
Estimated 5-year progression-free and disease-free survival rates of 80% were observed after a median follow-up of 42 months. The overall recurrent rate was 18%. Grade 3 neutropenia and anemia were noted in only 5.9% and 2.9%, respectively. All acute toxicities were transient and were manageable. There were no treatment-related deaths or late toxicities.
Conclusion:
For appropriately selected patients with bulky stage IB-IIA cervical cancer, concurrent cisplatin-based chemoradiation followed by adjuvant hysterectomy offers an effective treatment option with acceptable toxicity.
